Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.70 |
| ▸ | RET | P07949 | 1/20 | 0.70 |
| ▸ | KIF5B | P33176 | 1/20 | 0.70 |
| ▸ | EGFR | P00533 | 3/20 | 0.60 |
| ▸ | LCK | P06239 | 2/20 | 0.59 |
| ▸ | AURKA | O14965 | 1/20 | 0.57 |
| ▸ | MET | P08581 | 1/20 | 0.57 |
| ▸ | TEK | Q02763 | 1/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.57 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.57 |
| ▸ | CSF1R | P07333 | 2/20 | 0.55 |
| ▸ | BRAF | P15056 | 2/20 | 0.54 |
| ▸ | RAF1 | P04049 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.53 |
| ▸ | FLT4 | P35916 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4360537 | 0.90 | KDR (0.65) | KDRRETKIF5BEGFRLCK | |
| SCHEMBL5824492 | 0.86 | LCK (0.67) | KDRRETKIF5BEGFRLCK | |
| SCHEMBL1012099 | 0.85 | KDR (0.70) | KDRRETKIF5BEGFRLCK | |
| SCHEMBL5201680 | 0.84 | KDR (0.65) | KDRRETKIF5BEGFRLCK | |
| SCHEMBL5959059 | 0.84 | KDR (0.71) | KDRRETKIF5BEGFRLCK | |
| SCHEMBL2481753 | 0.83 | LCK (0.66) | KDRRETKIF5BEGFRLCK | |
| SCHEMBL4365791 | 0.83 | KDR (0.74) | KDRRETKIF5BEGFRLCK | |
| SCHEMBL23457663 | 0.83 | LCK (0.74) | KDRRETKIF5BEGFRLCK | |
| SCHEMBL4668514 | 0.82 | KDR (0.74) | KDRRETKIF5BEGFRLCK | |
| SCHEMBL31616965 | 0.82 | KDR (0.74) | KDRRETKIF5BEGFRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1638954-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | U.S. PATENT OPERATIONS | 2004-10-21 | — | — | US | disclosed |
| WO-2004085425-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209892-A1 | Heterocyclic compounds and methods of use | VHL, NQO1, HPGDS | KDR 83/4885RET 1463/4885KIF5B 4525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.